Welcome to our dedicated page for Verrica Pharmaceuticals news (Ticker: VRCA), a resource for investors and traders seeking the latest updates and insights on Verrica Pharmaceuticals stock.
Verrica Pharmaceuticals Inc., headquartered in West Chester, Pennsylvania, is a clinical-stage medical dermatology company dedicated to developing and commercializing innovative treatments for skin diseases. Founded in 2013, the company’s primary focus is on addressing unmet needs in dermatology through unique product candidates. Its lead product, YCANTH™ (cantharidin), is the first FDA-approved treatment for molluscum contagiosum, a highly contagious viral skin infection that primarily affects children.
The company’s flagship product, VP-102, is developed for the treatment of molluscum contagiosum and is currently in development for the treatment of common warts and external genital warts. VP-102 has successfully completed a Phase II clinical trial for common warts and a Phase I trial for genital warts. The innovative formulation of cantharidin in VP-102 provides precise topical dosing, making it a safe and effective solution for these conditions.
Verrica is also advancing another cantharidin-based product, VP-103, aimed at treating plantar warts. Furthermore, the company has a worldwide license agreement with Lytix Biopharma AS to develop and commercialize VP-315 (formerly LTX-315 and VP-LTX-315) for dermatologic oncology indications, including non-melanoma skin cancers such as basal cell carcinoma and squamous cell carcinoma.
In addition to its product development efforts, Verrica emphasizes strong partnerships and intellectual property strategies. The company has also recently amended its licensing agreement with Torii Pharmaceutical Co. Ltd. to jointly conduct a global pivotal Phase 3 clinical trial for common warts. This collaboration highlights Verrica’s commitment to expanding its product reach and addressing significant dermatological needs worldwide.
Verrica’s financial health is bolstered by its ongoing commercial operations and strategic agreements. The company’s recent achievements include securing a permanent J-code for YCANTH™ and receiving New Chemical Entity (NCE) status from the FDA, which grants a minimum of five years of regulatory exclusivity. These milestones are pivotal in driving the commercial success and adoption of YCANTH™ in the market.
For additional information and updates on Verrica Pharmaceuticals Inc., including recent news and investor relations, visit their website at www.verrica.com.
FAQ
What is the current stock price of Verrica Pharmaceuticals (VRCA)?
What is the market cap of Verrica Pharmaceuticals (VRCA)?
What is Verrica Pharmaceuticals Inc. known for?
What are the key products of Verrica Pharmaceuticals?
Where is Verrica Pharmaceuticals headquartered?
What recent achievements has Verrica Pharmaceuticals accomplished?
Who are Verrica Pharmaceuticals' key partners?
What is YCANTH™ used for?
What is the significance of the FDA's New Chemical Entity status for YCANTH™?
What is the focus of Verrica Pharmaceuticals' clinical trials?
How does Verrica Pharmaceuticals contribute to dermatology?
Where can I find more information about Verrica Pharmaceuticals?
